Lenvatinib Combined With Transarterial Chemoembolization as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Phase III, Randomized Clinical Trial (LAUNCH)

Abstract

The addition of TACE to LEN improves clinical outcomes and is a potential first-line treatment for patients with advanced HCC.